Skip to content

Jerome Beck

University of California, Berkeley

2 papers in the library · 120 citations · publishing 1986-2019

Papers

Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD

Journal of Psychoactive Drugs March 8, 2019 William P. Barone, Jerome Beck, Michiko Mitsunaga-Whitten et al. 63 citations

In a long-term follow-up of a phase 2 clinical trial, veterans, firefighters, and police officers with chronic, treatment-resistant PTSD reported lasting personal benefits and enhanced quality of life one year after MDMA-assisted psychotherapy. Interviews with 19 of 24 participants were analyzed using interpretative phenomenological analysis. All participants described benefits that went beyond symptom reduction, such as improved relationships and well-being. The findings suggest that qualitative methods can capture treatment effects that standard symptom scales may miss. The authors discuss limitations of the study and recommend improved qualitative research protocols for future trials.

DOI: 10.1080/02791072.2019.1580805 MDMA Thematic analysis Qualitative research Interpretative phenomenological analysis +6

Designer Drug Confusion: A Focus on MDMA

Journal of Drug Education September 1, 1986 Jerome Beck, Patricia Morgan 57 citations

MDMA, also called Ecstasy or Adam, is a designer drug with both stimulant and psychedelic properties that creates a unique effect sought by recreational users. Despite its recent illegality and growing evidence of neurotoxicity, interest in MDMA is expected to persist. The article examines the drug's recreational appeal and therapeutic potential, concluding that much more research is needed to understand both its possible benefits and risks.

DOI: 10.2190/tw2b-2p4a-kgum-6102 MDMA Ecstasy Stimulant Recreational drug +8